(3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]-N,N-diethylpiperidine-3-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: (3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]-N,N-diethylpiperidine-3-carboxamide
• 化学式: C₃₀H₃₇N₃O₂
• 分子量: 471.6
• InChiKey: TXUIRLUAKARNPD-XMMPIXPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  43.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]-N,N-diethylpiperidine-3-carboxamide 、 乙基溴化镁 、 四氢呋喃 在 氮气 、 甲醇 、 二氯甲烷 、 sodium hydroxide 、 碳酸氢钠 、 Sodium sulfate-III 、 crude product 、 silica gel 、 methanol-dichloromethane 作用下， 反应 16.5h， 以to give the title compound (3.2 mg, 15%)的产率得到Anthracen-9-yl-[3-(1-ethyl-1-hydroxy-propyl)-[1,4']bipiperidinyl-1'-yl]-methanone
  参考文献：
  名称：

  Acetyl-CoA carboxylase inhibitors

  摘要：

  乙酰辅酶A羧化酶抑制剂，含有这种化合物的制药组合物以及使用这种化合物治疗代谢综合征，包括动脉粥样硬化、糖尿病和肥胖症的用途。

  公开号：

  US06979741B2

文献信息

• Treatment of viral infections by modulation of host cell metabolic pathways
  申请人：THE TRUSTEES OF PRINCETON UNIVERSITY

  公开号：EP2581081A2

  公开（公告）日：2013-04-17

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in "suicide" of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models.; Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

  描述了病毒感染时某些代谢物浓度和通量的变化。所涉及的代谢途径中的宿主细胞酶被选为干预目标；即恢复代谢通量以不利于病毒复制，或进一步改变代谢通量导致病毒感染细胞（而非未感染细胞）"自杀 "以限制病毒传播。虽然可以选择相关代谢途径中的任何一种酶，但这些代谢途径关键控制点上的关键酶更适合作为候选的抗病毒药物靶点。这些酶的抑制剂可用于逆转或重定向病毒感染的影响。候选药物通过体外和宿主细胞以及动物模型中的筛选试验进行抗病毒活性测试；然后用动物模型测试候选化合物在预防和治疗病毒感染方面的疗效。展示酶抑制剂的抗病毒活性。
• ACC INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1478437B1

  公开（公告）日：2005-08-31
• INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM
  申请人：Neuera Pharmaceuticals, Inc.

  公开号：EP2150265A1

  公开（公告）日：2010-02-10
• NEOSORAPHENS AND THEIR USE IN THE TREATMENT OR PREVENTION OF A VIRAL INFECTION OR OF A TH17-ASSOCIATED INFLAMMATORY AND/OR AUTOIMMUNE DISEASE
  申请人：Helmholtz-Zentrum für Infektionsforschung GmbH

  公开号：EP3129385B1

  公开（公告）日：2018-06-06
• NEOSORAPHENS
  申请人：Helmoltz-Zentrum für Infektionsforschung GmbH

  公开号：US20170029436A1

  公开（公告）日：2017-02-02

  The present invention relates to compounds according to general formula (I); to compositions, including a pharmaceutical formulation and a combination preparation comprising one or more of the compound (s); to a process for their preparation; to uses thereof, including the use in the treatment or prevention of a viral infection or a Th17-associated inflammatory and/or autoimmune disease.